fda compounding semaglutide enforcement 2025 news What Patients Need to Know About the GLP-1 Policy Changes Judge Upholds FDA Deadline Ending

Conclusion Trials demonstrate actual evidence, not merely transient alteration

Greater than 78% of participants on 15 mg achieved 15% weight loss, and 36% achieved 25%

This US FDA-backed model will allow pharmaceutical companies to pair software with their drugs, such as GLP-1 medications, to improve patient outcomes

Anyone who has used an unlicensed product labelled as retatrutide should seek medical advice if side effects are severe, persistent or worsening

Clinical trial data can show what happened in a study population

The regulatory and supply landscape for retatrutide and semaglutide could not be more different right now, and these practical realities will determine which option is available to most people for the foreseeable future